MAPT and pancreatic adenocarcinoma: After cross-validation with publicly available DNA methylation data, including 339 pancreatic adenocarcinoma (PAAD) patients and 357 normal controls, we successfully identified eight probes from six differentially methylated genes, containing TRIM73, FAM150A, EPB41L3, SIX3, MIR663, MAPT, LOC100128977, and LOC100130148, which could be used as potential biomarkers for early detection for PDAC patients.